B-intervention	0	7	Vaginal
I-intervention	8	10	pH
I-intervention	10	11	-
I-intervention	11	19	balanced
I-intervention	20	23	gel
O	24	27	for
O	28	31	the
O	32	39	control
O	40	42	of
O	43	51	atrophic
O	52	61	vaginitis
O	62	67	among
O	68	74	breast
O	75	81	cancer
O	82	91	survivors
O	91	92	:
O	93	94	a
O	95	105	randomized
O	106	116	controlled
O	117	122	trial
O	122	123	.

O	124	126	To
O	127	135	estimate
O	136	139	the
O	140	147	effects
O	148	150	of
O	151	158	vaginal
O	159	161	pH
O	161	162	-
O	162	170	balanced
O	171	174	gel
O	175	177	on
O	178	185	vaginal
O	186	194	symptoms
O	195	198	and
O	199	206	atrophy
O	207	209	in
O	210	216	breast
O	217	223	cancer
O	224	233	survivors
O	234	241	treated
O	242	246	with
O	247	259	chemotherapy
O	260	262	or
O	263	272	endocrine
O	273	280	therapy
O	280	281	.

O	282	286	This
O	287	290	was
O	291	292	a
O	293	303	randomized
O	303	304	,
O	305	311	double
O	311	312	-
O	312	317	blind
O	317	318	,
O	319	326	placebo
O	326	327	-
O	327	337	controlled
O	338	343	study
O	343	344	.

B-eligibility	345	351	Breast
I-eligibility	352	358	cancer
I-eligibility	359	368	survivors
I-eligibility	369	372	who
I-eligibility	373	384	experienced
I-eligibility	385	394	menopause
I-eligibility	395	400	after
I-eligibility	401	413	chemotherapy
I-eligibility	414	416	or
I-eligibility	417	426	endocrine
I-eligibility	427	434	therapy
O	435	439	were
O	440	451	voluntarily
O	452	460	enrolled
O	461	464	and
O	465	473	randomly
O	474	486	administered
O	487	494	vaginal
O	495	502	topical
O	503	505	pH
O	505	506	-
O	506	514	balanced
O	515	518	gel
O	519	521	or
B-control	522	529	placebo
O	530	535	three
O	536	541	times
O	542	545	per
O	546	550	week
O	551	554	for
O	555	557	12
O	558	563	weeks
O	563	564	.

B-outcome-Measure	565	572	Vaginal
I-outcome-Measure	573	580	dryness
O	581	584	and
B-outcome-Measure	585	596	dyspareunia
O	597	601	were
O	602	610	measured
O	611	613	by
O	614	620	visual
O	621	627	analog
O	628	633	scale
O	633	634	,
O	635	642	vaginal
O	643	649	health
O	650	655	index
O	655	656	,
O	657	660	and
O	661	668	vaginal
O	669	671	pH
O	671	672	.

O	673	676	The
O	677	688	endometrium
O	689	692	and
O	693	698	ovary
O	699	703	were
O	704	713	evaluated
O	714	716	by
O	717	729	transvaginal
O	730	745	ultrasonography
O	745	746	.

O	747	752	Among
B-total-participants	753	755	98
O	756	764	enrolled
O	765	770	women
O	770	771	,
B-total-participants	772	774	86
O	775	784	completed
O	785	788	the
O	789	798	treatment
O	799	800	(
O	800	801	n
O	801	802	=
B-intervention-participants	802	804	44
O	805	808	and
O	809	810	n
O	810	811	=
B-control-participants	811	813	42
O	814	817	for
O	818	821	the
O	822	824	pH
O	824	825	-
O	825	833	balanced
O	834	837	gel
O	838	843	group
O	844	847	and
O	848	855	placebo
O	856	861	group
O	861	862	,
O	863	875	respectively
O	875	876	)
O	876	877	.

B-outcome	878	885	Vaginal
I-outcome	886	893	dryness
O	894	897	and
B-outcome	898	909	dyspareunia
O	910	918	improved
O	919	923	more
O	924	926	in
O	927	930	the
O	931	933	pH
O	933	934	-
O	934	942	balanced
O	943	946	gel
O	947	952	group
O	953	957	than
O	958	960	in
O	961	964	the
O	965	972	placebo
O	973	978	group
O	979	980	(
B-outcome	980	988	baseline
O	989	993	mean
B-iv-cont-mean	994	995	8
I-iv-cont-mean	995	996	.
I-iv-cont-mean	996	998	20
O	999	1007	compared
O	1008	1012	with
B-outcome	1013	1016	end
I-outcome	1016	1017	-
I-outcome	1017	1022	point
O	1023	1027	mean
B-cv-cont-mean	1028	1029	4
I-cv-cont-mean	1029	1030	.
I-cv-cont-mean	1030	1032	23
O	1033	1034	[
O	1034	1035	P
O	1035	1036	=
O	1036	1037	.
O	1037	1040	001
O	1040	1041	]
O	1042	1045	and
B-iv-cont-mean	1046	1047	8
I-iv-cont-mean	1047	1048	.
I-iv-cont-mean	1048	1050	23
O	1051	1059	compared
O	1060	1064	with
B-cv-cont-mean	1065	1066	5
I-cv-cont-mean	1066	1067	.
I-cv-cont-mean	1067	1069	48
O	1070	1071	[
O	1071	1072	P
O	1072	1073	=
O	1073	1074	.
O	1074	1077	040
O	1077	1078	]
O	1078	1079	,
O	1080	1092	respectively
O	1092	1093	)
O	1093	1094	.

O	1095	1102	Vaginal
O	1103	1105	pH
O	1105	1106	-
O	1106	1114	balanced
O	1115	1118	gel
O	1119	1126	reduced
O	1127	1130	the
B-outcome	1131	1138	vaginal
I-outcome	1139	1141	pH
O	1142	1143	(
O	1143	1146	gel
O	1146	1147	:
B-outcome	1148	1156	baseline
O	1157	1161	mean
B-iv-cont-mean	1162	1163	6
I-iv-cont-mean	1163	1164	.
I-iv-cont-mean	1164	1166	49
O	1167	1175	compared
O	1176	1180	with
B-outcome	1181	1184	end
I-outcome	1184	1185	-
I-outcome	1185	1190	point
O	1191	1195	mean
B-iv-cont-mean	1196	1197	5
I-iv-cont-mean	1197	1198	.
I-iv-cont-mean	1198	1200	00
O	1200	1201	;
O	1202	1209	placebo
O	1209	1210	:
O	1211	1212	6
O	1212	1213	.
O	1213	1215	22
O	1216	1224	compared
O	1225	1229	with
O	1230	1231	5
O	1231	1232	.
O	1232	1234	69
O	1235	1236	[
O	1236	1237	P
O	1237	1238	<
O	1238	1239	.
O	1239	1242	001
O	1242	1243	]
O	1243	1244	)
O	1244	1245	,
O	1246	1249	and
O	1250	1258	enhanced
B-outcome	1259	1266	vaginal
I-outcome	1267	1277	maturation
I-outcome	1278	1283	index
O	1284	1285	(
O	1285	1288	gel
O	1288	1289	:
B-iv-cont-mean	1290	1292	45
I-iv-cont-mean	1292	1293	.
I-iv-cont-mean	1293	1294	5
O	1295	1303	compared
O	1304	1308	with
B-iv-cont-mean	1309	1311	51
I-iv-cont-mean	1311	1312	.
I-iv-cont-mean	1312	1313	2
O	1313	1314	;
O	1315	1322	placebo
O	1322	1323	:
B-cv-cont-mean	1324	1326	46
I-cv-cont-mean	1326	1327	.
I-cv-cont-mean	1327	1328	4
O	1329	1337	compared
O	1338	1342	with
B-cv-cont-mean	1343	1345	47
I-cv-cont-mean	1345	1346	.
I-cv-cont-mean	1346	1347	9
O	1348	1349	[
O	1349	1350	P
O	1350	1351	<
O	1351	1352	.
O	1352	1355	001
O	1355	1356	]
O	1356	1357	)
O	1358	1361	and
B-outcome	1362	1369	vaginal
I-outcome	1370	1376	health
I-outcome	1377	1382	index
O	1383	1384	(
O	1384	1387	gel
O	1387	1388	:
B-iv-cont-mean	1389	1391	15
I-iv-cont-mean	1391	1392	.
I-iv-cont-mean	1392	1393	8
O	1394	1402	compared
O	1403	1407	with
B-iv-cont-mean	1408	1410	21
I-iv-cont-mean	1410	1411	.
I-iv-cont-mean	1411	1412	1
O	1412	1413	;
O	1414	1421	placebo
B-cv-cont-mean	1422	1424	14
I-cv-cont-mean	1424	1425	.
I-cv-cont-mean	1425	1426	3
O	1427	1435	compared
O	1436	1440	with
B-cv-cont-mean	1441	1443	16
I-cv-cont-mean	1443	1444	.
I-cv-cont-mean	1444	1446	98
O	1447	1448	[
O	1448	1449	P
O	1449	1450	=
O	1450	1451	.
O	1451	1454	002
O	1454	1455	]
O	1455	1456	)
O	1456	1457	.

O	1458	1463	There
O	1464	1467	was
O	1468	1470	no
O	1471	1482	significant
O	1483	1493	difference
O	1494	1496	in
B-outcome	1497	1504	adverse
I-outcome	1505	1512	effects
O	1513	1520	between
O	1521	1524	the
O	1525	1528	two
O	1529	1535	groups
O	1536	1542	except
O	1543	1546	for
O	1547	1551	mild
O	1552	1562	irritation
O	1563	1565	at
O	1566	1569	the
O	1570	1575	early
O	1576	1580	time
O	1581	1583	of
O	1584	1586	pH
O	1586	1587	-
O	1587	1595	balanced
O	1596	1599	gel
O	1600	1614	administration
O	1614	1615	.

O	1616	1623	Vaginal
O	1624	1626	pH
O	1626	1627	-
O	1627	1635	balanced
O	1636	1639	gel
O	1640	1645	could
O	1646	1653	relieve
O	1654	1661	vaginal
O	1662	1670	symptoms
O	1671	1674	and
O	1675	1682	improve
O	1683	1690	vaginal
O	1691	1697	health
O	1698	1700	in
O	1701	1707	breast
O	1708	1714	cancer
O	1715	1724	survivors
O	1725	1728	who
O	1729	1733	have
O	1734	1745	experienced
O	1746	1755	menopause
O	1756	1761	after
O	1762	1768	cancer
O	1769	1778	treatment
O	1778	1779	.

O	1780	1794	ClinicalTrials
O	1794	1795	.
O	1796	1799	gov
O	1799	1800	,
O	1801	1804	www
O	1804	1805	.
O	1806	1820	clinicaltrials
O	1820	1821	.
O	1821	1824	gov
O	1824	1825	,
O	1826	1837	NCT00607295
O	1837	1838	.
O	1838	1839	I
O	1839	1840	.
